Piramal Pharma Limited

NSE PPLPHARMA.NS

Piramal Pharma Limited EBITDA Margin for the year ending March 31, 2024: 16.73%

Piramal Pharma Limited EBITDA Margin is 16.73% for the year ending March 31, 2024, a 39.96% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Piramal Pharma Limited EBITDA Margin for the year ending March 31, 2023 was 11.95%, a -69.44% change year over year.
Piramal Pharma Limited EBITDA Margin for the year ending March 31, 2022 was 39.10%, a 87.97% change year over year.
Piramal Pharma Limited EBITDA Margin for the year ending March 31, 2021 was 20.80%.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NSE: PPLPHARMA.NS

Piramal Pharma Limited

CEO	Mr. Peter Daniel DeYoung
IPO Date	Oct. 19, 2022
Location	India
Headquarters	507, Skyline Wealth Space
Employees	6,719
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Piramal Pharma Limited operates as a pharmaceutical company. It sells a portfolio of pharma products, as well as provides various pharma services, including injection, HPAPI, etc. The company was incorporated in 2020 and is based in Mumbai, India. Piramal Pharma Limited operates as a subsidiary of Piramal Enterprises Limited.

Key trends

Past 5 years